CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer.

Journal: European radiology
Published Date:

Abstract

BACKGROUND: Definitive chemoradiation is the primary treatment for locally advanced head and neck carcinoma (LAHNSCC). Optimising outcome predictions requires validated biomarkers, since TNM8 and HPV could have limitations. Radiomics may enhance risk stratification.

Authors

  • Gema Bruixola
    Medical Oncology Department, Hospital Clinico Universitario de Valencia-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Delfina Dualde-Beltrán
    Radiology Department, Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain.
  • Ana Jimenez-Pastor
    QUIBIM SL, Valencia, Spain. anajimenez@quibim.com.
  • Anna Nogué
    Quibim-Quantitative Imaging Biomarkers in Medicine, Valencia, Spain.
  • Fuensanta Bellvís
    Quibim-Quantitative Imaging Biomarkers in Medicine, Valencia, Spain.
  • Almudena Fuster-Matanzo
    Quantitative Imaging Biomarkers in Medicine (Quibim), Valencia, Spain.
  • Clara Alfaro-Cervello
    From the Departments of Digestive Diseases (D.M.A., M.P.B., D.E.G.), Pathology (C.A.C., C.M.A., A.F.), and Gastroenterology and Hepatology (D.M.A.), Clinic University Hospital, INCLIVA Health Research Institute, Avenida Blasco Ibáñez 17, 46010 Valencia, Spain; Biomedical Imaging Research Group (GIBI2), La Fe Health Research Institute, Valencia, Spain (D.M.A., A.R.O., L.M.B.); Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain (A.J.P., Á.A.B.); University of Valencia, Faculty of Medicine, Valencia, Spain (C.A.C., A.F., D.E.G., M.A.S.); Departments of Pathology (M.B., J.P.R.), Digestive Diseases (E.V.P., M.G.T.), and Radiology (A.P.G., L.M.B.) and the Hepatology and Liver Transplantation Unit (V.A.), La Fe University and Polytechnic Hospital, Valencia, Spain; Departments of Digestive Diseases (A.G.P., S.B.) and Pathology (V.P.), Hospital Arnau de Vilanova, Valencia, Spain; CIBERehd (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Madrid, Spain (S.B., V.A.); and Río Hortega, Instituto Salud Carlos III, Madrid, Spain (D.M.A.).
  • Nuria Grimalt
    Medical Oncology Department, Hospital Clinico Universitario de Valencia-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Nader Salhab-Ibáñez
    Radiology Department, Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain.
  • Vicente Escorihuela
    Otorhinolaryngology Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
  • María Eugenia Iglesias
    Oral and Maxillary Surgery Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
  • María Maroñas
    Radiation Oncology Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
  • Angel Alberich-Bayarri
    QUIBIM SL, Valencia, Spain.
  • Andrés Cervantes
    Medical Oncology Department, Hospital Clinico Universitario de Valencia-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. andres.cervantes@uv.es.
  • Noelia Tarazona
    Medical Oncology Department, Hospital Clinico Universitario de Valencia-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. noetalla@incliva.es.